Home > Result Summaries: Compounds > Combined Measles, Mumps, Rubella, Varicella Vaccine > Result Summary for 208136/006

Result Summary for 208136/006

Result Summary

Protocol ID:	208136/006
Clinical Study ID:	208136/006 (MeMuRu-OKA-006)
Official Title:	Study evaluating in healthy children safety and immunogenicity of GSK Bios' combined Measles-Mumps-Rubella-Varicella vaccine, compared to GSK Bios' Varicella and Measles-Mumps-Rubella vaccines admind as separate injections
Phase:	Phase 2
Study Indications or Diseases:	Measles-Mumps-Rubella-Varicella Vaccine
Generic Name:	Combined Measles, Mumps, Rubella, Varicella Vaccine
Trade/Product Name:	Priorix-Tetra;Priorix-Tetra
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Kreth HW et al. (2008) Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix™). Biodrugs. 22 (6): 387-402. Knuf M et al. (2008) A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc). 44(4):279-292. Zepp F et al. Antibody persistence over two year follow-up period after vaccination at 12-24 months of age with either an experimental measles-mumps-rubella-varicella (MMRV) vaccine, or separate concomitant injections of measles-mumps-rubella (MMR, Priorix™) plus varicella (V, Varilrix™) vaccines. Abstract presented at 4th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), Warsaw, Poland, 1-4 September 2005.